By giving their patient the correct diagnosis, clinicians avoided costlier treatments for thrombotic thrombocytopenic purpura (TTP) like plasmapheresis.
Pseudo-thrombotic microangiopathy (pseudo-TMA) is relatively easy to treat, but it is also easy to mistake for a much more serious condition, thrombotic thrombocytopenic purpura (TTP).
In a new report in Cureus, investigators explained a case in which a patient with vitamin B12 deficiency received a diagnosis of pseudo-TMA. They said the case offers important insights about how to avoid a burdensome misdiagnosis.
Only about 2.5% of people with vitamin B12 deficiency have pseudo-TMA, wrote the case report’s authors. Patients with a severe deficiency can present with anemia, thrombocytopenia, and schistocytosis, she said.
Those are similar symptoms to those exhibited by patients with primary TMA, a category that includes TTP, Shiga toxin–mediated hemolytic uremic syndrome (HUS), drug-induced TMA, and complement-mediated TMA, the authors noted.
Although pseudo-TMA can look like TTP, their treatment and implications are very different, the study’s authors said.
“It is essential to distinguish pseudo-thrombotic microangiopathy from TTP and HUS to avoid expensive treatments like plasmapheresis, which has a spectrum of adverse effects, including electrolyte abnormalities, coagulation factor abnormalities, allergic reactions, and problems with fluid overload,” they wrote.
The patient that is the subject of their report was a 69-year-old man with a history of gastroesophageal reflux disease who sought care a week after developing a rash in his inguinal area, along with fatigue and a 10-pound weight loss over the previous few months.
Initial cardiovascular, respiratory, neurologic, and abdominal exams turned up nothing out of the ordinary, the authors said.
Doctors decided to admit him to the hospital after his initial lab workup showed a hemoglobin drop from 14 to 7.5 g/dL, a mean corpuscular volume (MCV) of 124, and a vitamin B12 level below 50. He underwent a fecal occult blood test, which the investigators said was negative. The patient had previously been prescribed cephalexin and topical ketoconazole for his rash, they noted.
The next day, labs showed a lactate dehydrogenase level of 824 U/L, the study investigators said.
“A complete blood count revealed thrombocytopenia of 109 and 1+ schistocytes,” the authors said. “His total bilirubin was 2.1, and indirect bilirubin was 1.6; folate and thyroid-stimulating hormone were normal.”
The patient received 2 units of blood transfusions and vitamin B12 injections of 1000 mcg/d. After consulting with hematology, the investigators put him on high-dose prednisone out of concern about possible drug-induced hemolytic anemia. When his direct antiglobulin test was negative, he was tapered off steroids.
“On follow-up with hematology after a month, it was found that his haptoglobin was less than 15,” the authors said. “His repeat bloodwork showed normalization of all his lab values, including hemoglobin, MCV, bilirubin, and lactate dehydrogenase.”
They said it is important to differentiate pseudo-TMA from actual TMA, in large part because the former is simple to treat and the latter requires emergency care.
They added that clinicians should also be more cautious when treating patients who have specific risk factors for vitamin B12 deficiency.
“For instance, patients who are vegetarians or others with malabsorption tendencies, such as bariatric surgery patients,” they wrote.
Reference
Sathi T, Luhadia K, Yashi K, et al. Pseudo-thrombotic thrombocytopenic purpura due to severe vitamin B12 deficiency: a case report. Cureus. Published online June 10, 2023. doi:10.7759/cureus.40212
Bridging the Gaps: New Strategies for Preventing Cardiovascular Disease
July 31st 2025During the Addressing Cardiovascular Risk and Intervening Early webinar, experts discussed innovative strategies for cardiovascular disease prevention, emphasizing risk assessment, lifestyle changes, and collaborative care to improve patient outcomes.
Read More
Trends in Insulin Out-of-Pocket Costs and Use Disparities, 2008-2021
July 31st 2025Given trends in cost and use, insulin out-of-pocket cost reduction policies would be more efficient if they targeted members in high-deductible health plans with savings options and low-income patients.
Read More
The Legal Architecture of Psychedelic Therapy: Risks, Responsibilities, and Reimbursement Realities
July 30th 2025Key legal, ethical, and compliance considerations for managed care professionals navigating the evolving landscape of psychedelic-assisted therapy include regulatory risks, data privacy challenges, reimbursement limitations, and the need for culturally informed care models.
Read More